Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
    Journal Article

    Cruz, C.; Castroviejo-Bermejo, M.; Gutiérrez-Enríquez, S.; Llop-Guevara, A.; Ibrahim, Y. H.; Gris-Oliver, A.; Bonache, S.; Morancho, B.; Bruna, A.; Rueda, O. M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessing tumor infiltrating lymphocytes and genomic alterations in pre-treatment core biopsy and correlation with response to neoadjuvant chemotherapy
    Meeting Abstract

    Zeng, J.; Brogi, E.; Floris, G.; Turashvili, G.; Razavi, P.; Baselga, J.; Sanford, R.; Ross, D.; Solit, D.; Berger, M. F.; more...
    Modern Pathology (2018)

    Fulltext@MSK | Save
  • PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
    Meeting Abstract

    Prat, A.; Brase, J. C.; Cheng, Y.; Nuciforo, P.; Paré, L.; Pascual, T.; Martínez, D.; Galván, P.; Vidal, M.; Adamo, B.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study
    Journal Article

    Diamond, E. L.; Subbiah, V.; Lockhart, A. C.; Blay, J. Y.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J.; Erinjeri, J. P.; Torrisi, J.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)
    Meeting Abstract

    Wongchenko, M. J.; Dent, R.; Kim, S. B.; Saura, C.; Oliveira, M.; Baselga, J.; Kapp, A. V.; Chan, W. Y.; Singel, S. M.; Maslyar, D. J.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Oliveira, M.; Ciruelos, E.; Tamura, K.; El-Khoueiry, A.; Mita, A.; You, B.; Renouf, D. J.; Sablin, M. P.; Lluch, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial
    Meeting Abstract

    Sotiriou, C.; Rothé, F.; Maetens, M.; Fumagalli, D.; Brown, D. N.; Salgado, R.; Bradbury, I.; Pusztai, L.; Harbeck, N.; Ignatiadis, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial
    Meeting Abstract

    Venet, D.; Rothé, F.; Dupont, F.; Maetens, M.; Fumagalli, D.; Salgado, R.; Bradbury, I.; Pusztai, L.; Harbeck, N.; Izquierdo, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial
    Meeting Abstract

    Powles, R.; Redmond, D.; Sotiriou, C.; Loi, S.; Fumagalli, D.; Nuciforo, P.; Harbeck, N.; de Azambuja, E.; Sarp, S.; Di Cosimo, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer
    Meeting Abstract

    Rimm, D. L.; Carvajal-Hausdorf, D.; Harbeck, N.; Fumagalli, D.; Rodrik-Outmezguine, V.; delaPena, L.; deAzambuja, E.; Huober, J.; Baselga, J.; Piccart, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save